Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $5628.0.

  • bioAffinity Technologies' Gains from Sales and Divestitures fell 9410.67% to $5628.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5628.0, marking a year-over-year decrease of 9410.67%. This contributed to the annual value of $31973.0 for FY2024, which is 4585.53% down from last year.
  • bioAffinity Technologies' Gains from Sales and Divestitures amounted to $5628.0 in Q3 2025, which was down 9410.67% from $172660.0 recorded in Q2 2025.
  • bioAffinity Technologies' Gains from Sales and Divestitures' 5-year high stood at $172660.0 during Q2 2025, with a 5-year trough of $5628.0 in Q3 2025.
  • For the 4-year period, bioAffinity Technologies' Gains from Sales and Divestitures averaged around $56080.2, with its median value being $31973.0 (2024).
  • Over the last 5 years, bioAffinity Technologies' Gains from Sales and Divestitures had its largest YoY gain of 242205.67% in 2025, and its largest YoY loss of 9410.67% in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Gains from Sales and Divestitures stood at $29728.0 in 2022, then skyrocketed by 98.64% to $59051.0 in 2023, then plummeted by 45.86% to $31973.0 in 2024, then tumbled by 82.4% to $5628.0 in 2025.
  • Its last three reported values are $5628.0 in Q3 2025, $172660.0 for Q2 2025, and $92601.0 during Q1 2025.